SCHEMBL3770906

SCHEMBL3770906

O=C(CN1CCN(c2ccccc2F)CC1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.57
KMT2A Q03164 7/20 0.55
MEN1 O00255 6/20 0.55
TSHR P16473 3/20 0.55
LMNA P02545 3/20 0.55
MAPT P10636 1/20 0.55
HSD17B10 Q99714 2/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
MAPK1 P28482 1/20 0.54
KDM4E B2RXH2 3/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PARP1 P09874 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13004958 0.99 KMT2A (0.56) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL3768876 0.97 KMT2A (0.56) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL3769112 0.87 MEN1 (0.55) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL3773704 0.87 GRM5 (0.48) ALDH1A1KMT2AMEN1TSHRHSD17B10
SCHEMBL3763088 0.86 TSHR (0.58) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL20122620 0.86 TSHR (0.58) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL13004961 0.86 MEN1 (0.54) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL3774214 0.85 TSHR (0.56) ALDH1A1KMT2AMEN1TSHRMAPT
SCHEMBL3767597 0.84 HTR7 (0.52) ALDH1A1KMT2AMEN1TSHRLMNA
SCHEMBL3767578 0.83 ALDH1A1 (0.72) ALDH1A1KMT2AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KMT2A 242/4885MEN1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.